Nicotine Addiction News and Research

RSS

Enrollment complete in Nabi's second NicVAX Phase III clinical trial for nicotine addiction

Nabi Biopharmaceuticals announced today that it has completed enrollment in the second Phase III clinical trial of NicVAX® (Nicotine Conjugate Vaccine), the company's innovative and proprietary investigational candidate vaccine being developed to treat nicotine addiction and prevent smoking relapse.

10 Nov 2010

NeuroDerm commences enrollment in ND0801 Phase 2a clinical study of ADD/ADHD in adults

NeuroDerm, Ltd. announced today that patient enrollment has begun in a Phase 2a clinical study of ND0801, a new product for the treatment of Attention Deficit Disorder/Attention Deficit Hyperactivity Disorder (ADD/ADHD) in adults. ND0801, based on a new, proprietary combination with nicotinic actions, is being developed as a dermal patch and will be evaluated for the treatment of cognitive impairment in several disorders including Alzheimer's disease, schizophrenia and advanced Parkinson's disease, among others.

9 Nov 2010

Pfizer's two new compounds may be effective in treating alcohol, nicotine dependence

Researchers at the Ernest Gallo Clinic and Research Center at the University of California, San Francisco, and Pfizer Inc., have determined that two new compounds may be effective in treating both alcohol and nicotine dependence at the same time.

4 Nov 2010

Alzheimer’s risk raised 157% with smoking: Study

A Kaiser Permanente study reported this Monday that heavy smoking in midlife more than doubles the odds of developing Alzheimer's disease. This study is one of the first of its kind to examine the long-term consequences of heavy smoking on Alzheimer's disease and vascular dementia explained the study's principal investigator, Rachel Whitmer, a research scientist with Kaiser Permanente in Oakland. The research is published in the Archives of Internal Medicine.

25 Oct 2010

Plant-derived compound for treatment of nicotine addiction also effective against alcoholism

South Dakota State University researchers have demonstrated for the first time that a plant-derived compound used to treat nicotine addiction also has significant effects against alcohol addiction.

21 Oct 2010

Nicotine reduction strategy should be an urgent research priority

After a major review of scientific information, six leading tobacco research and policy experts have concluded that a nicotine reduction strategy should be an urgent research priority because of its potential to profoundly reduce the death and disease from tobacco use. Their findings were published today in the journal Tobacco Control.

4 Oct 2010

Tobacco taxes help kick the habit

The hike in Australia’s tobacco tax has had an expected effect with almost 300,000 people quitting the habit. The tax increase arrived this April with a 25% rise in tobacco taxes. Polls now confirm that the cost of cigarettes are a powerful lever for improving public health, with only 16 per cent of smokers stating they would “continue to smoke at any price”.

23 Sep 2010

NIDA awards GeneGo SBIR grant to develop integrated systems biology platform for nicotine addiction research

GeneGo, Inc., the leading systems biology company, today announced that it has been awarded a grant from the National Institute on Drug Abuse to develop an integrated systems biology platform for research into the causes and treatment of tobacco dependence, nicotine addiction, smoking cessation and tobacco/nicotine withdrawal.

22 Sep 2010

FDA issues warning letters to five electronic cigarette distributors

The U.S. Food and Drug Administration today issued warning letters to five distributors for various violations of the Federal Food, Drug, and Cosmetic Act (FDCA) including unsubstantiated claims and poor manufacturing practices.

10 Sep 2010

NIH awards $6.5M for pharmacogenomics study of key mood-stabilizing drug for bipolar disorder

An international team, led by University of California, San Diego School of Medicine researchers, has been awarded a $6.5 million grant from the National Institutes of Health (NIH) to study the pharmacogenomics of a key mood-stabilizing drug used to treat bipolar disorder.

9 Sep 2010

NIH announces $161.3 million for expansion of Pharmacogenomics Research Network

The National Institutes of Health plans to spend $161.3 million over the next five years to expand the Pharmacogenomics Research Network (PGRN), a nationwide collaborative of scientists focused on understanding how genes affect a person's response to medicines.

8 Sep 2010

UC San Diego researchers receive grant to study pharmacogenomics for bipolar disorder

8 Sep 2010

NIH awards St. Jude $8.6M to focus on anticancer agent research in children

With its new expansion of the Pharmacogenomics Research Network (PGRN), the National Institutes of Health (NIH) awarded St. Jude Children's Research Hospital a prestigious grant to focus on anticancer agent research in children.

8 Sep 2010

Penn receives $12M NIH grant to study pharmacogenetics of nicotine addiction treatment

A variety of smoking cessation treatments are currently available for the more than 18 million adult Americans try to quit smoking each year, but success rates vary widely. Despite the importance of quitting smoking, more personalized approaches to smoking cessation treatment are needed to help smokers pick the right method that will work best for them. A major new personalized medicine clinical trial, led by addiction researchers at the University of Pennsylvania, will study how a smokers' genetic make-up influences their quitting success.

8 Sep 2010

UCSF scientists to receive two grants for personalized medicine research

UCSF scientists will receive two grants totaling $15.1 million over the next five years to expand their research into how genes affect an individual's response to medication and to strengthen a global network of researchers involved in these efforts.

7 Sep 2010

Nabi Biopharmaceuticals, Diosynth sign long-term commercial manufacturing agreement

Nabi Biopharmaceuticals announced today that it has entered into a long-term commercial manufacturing agreement with Diosynth RTP, Inc. for the manufacture of Drug Substance integral to the production of NicVAX, Nabi's innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse.

2 Sep 2010

Anti-smoking measures beefed up

Tasmanians are looking at one of the tightest tobacco control measures ever adopted. The Tasmanian Government is proposing a no-smoking zone at almost all public places including shopping malls and sporting venues and introducing smoke-free buffer zone around children's playgrounds.

31 Aug 2010

Study finds common risk factors linked with painkiller addiction

A new Geisinger study begins to unlock the puzzle of painkiller (opioid) addiction - why some people are more likely to become addicted than others. Geisinger investigators have found that patients with four common risk factors have a significantly higher risk of addiction. In addition, a history of severe drug dependence and drug abuse compounds the risk.

30 Aug 2010

Alexza Pharmaceuticals licenses Staccato nicotine technology to Cypress Bioscience

Alexza Pharmaceuticals, Inc. announced today that it has licensed its Staccato nicotine technology to Cypress Bioscience, Inc. The Staccato nicotine technology is a novel electronic multidose delivery system designed to help people stop smoking. The Staccato nicotine technology is intended to improve on a well-validated smoking cessation approach by delivering nicotine via inhalation, mimicking the nicotine effects of smoking without the harmful side effects associated with cigarettes.

26 Aug 2010

Nabi receives US patent for treatment and prevention of nicotine addiction with NicVAX conjugate vaccines

Nabi Biopharmaceuticals announced the receipt of a patent for treating and preventing nicotine addiction with NicVAX® and related nicotine conjugate vaccines. The United States Patent and Trademark office issued U.S. Patent No. 7,776,620 entitled "Hapten-carrier conjugates for treating and preventing nicotine addiction" for the exclusive use of methods for treating and preventing nicotine addiction with NicVAX and related nicotine vaccines. This patent runs through December 2018.

26 Aug 2010

Nicotine Addiction News and Research

Enrollment complete in Nabi's second NicVAX Phase III clinical trial for nicotine addiction

NeuroDerm commences enrollment in ND0801 Phase 2a clinical study of ADD/ADHD in adults

Pfizer's two new compounds may be effective in treating alcohol, nicotine dependence

Alzheimer’s risk raised 157% with smoking: Study

Plant-derived compound for treatment of nicotine addiction also effective against alcoholism

Nicotine reduction strategy should be an urgent research priority

Tobacco taxes help kick the habit

NIDA awards GeneGo SBIR grant to develop integrated systems biology platform for nicotine addiction research

FDA issues warning letters to five electronic cigarette distributors

NIH awards $6.5M for pharmacogenomics study of key mood-stabilizing drug for bipolar disorder

NIH announces $161.3 million for expansion of Pharmacogenomics Research Network

UC San Diego researchers receive grant to study pharmacogenomics for bipolar disorder

NIH awards St. Jude $8.6M to focus on anticancer agent research in children

Penn receives $12M NIH grant to study pharmacogenetics of nicotine addiction treatment

UCSF scientists to receive two grants for personalized medicine research

Nabi Biopharmaceuticals, Diosynth sign long-term commercial manufacturing agreement

Anti-smoking measures beefed up

Study finds common risk factors linked with painkiller addiction

Alexza Pharmaceuticals licenses Staccato nicotine technology to Cypress Bioscience

Nabi receives US patent for treatment and prevention of nicotine addiction with NicVAX conjugate vaccines

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News